JP2015508887A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508887A5
JP2015508887A5 JP2014555851A JP2014555851A JP2015508887A5 JP 2015508887 A5 JP2015508887 A5 JP 2015508887A5 JP 2014555851 A JP2014555851 A JP 2014555851A JP 2014555851 A JP2014555851 A JP 2014555851A JP 2015508887 A5 JP2015508887 A5 JP 2015508887A5
Authority
JP
Japan
Prior art keywords
protein
patient
inflammasome
level
cns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508887A (ja
JP6170071B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/024941 external-priority patent/WO2013119673A1/en
Publication of JP2015508887A publication Critical patent/JP2015508887A/ja
Publication of JP2015508887A5 publication Critical patent/JP2015508887A5/ja
Application granted granted Critical
Publication of JP6170071B2 publication Critical patent/JP6170071B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555851A 2012-02-06 2013-02-06 Ｃｎｓ損傷についてのバイオマーカーとしての自然免疫タンパク質 Active JP6170071B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261595254P 2012-02-06 2012-02-06
US61/595,254 2012-02-06
PCT/US2013/024941 WO2013119673A1 (en) 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury

Publications (3)

Publication Number Publication Date
JP2015508887A JP2015508887A (ja) 2015-03-23
JP2015508887A5 true JP2015508887A5 (enExample) 2016-02-25
JP6170071B2 JP6170071B2 (ja) 2017-07-26

Family

ID=48947960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555851A Active JP6170071B2 (ja) 2012-02-06 2013-02-06 Ｃｎｓ損傷についてのバイオマーカーとしての自然免疫タンパク質

Country Status (6)

Country Link
US (4) US20150185232A1 (enExample)
EP (1) EP2812697B1 (enExample)
JP (1) JP6170071B2 (enExample)
CA (1) CA2863417C (enExample)
ES (1) ES2630905T3 (enExample)
WO (1) WO2013119673A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
WO2021222263A2 (en) * 2020-04-27 2021-11-04 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
CA2948478A1 (en) * 2014-04-08 2015-10-15 University Of Florida Research Foundation, Incorporated Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
CN110461356A (zh) 2016-12-29 2019-11-15 迈阿密大学 用于调节肺中炎性体活性和炎症的方法
EP3685169A4 (en) * 2017-09-20 2021-09-08 University of Miami PROCESS FOR DETECTION OF INFLAMMASOME PROTEINS AS BIOMARKERS OF NEUROLOGICAL DISORDERS
US12130294B2 (en) 2018-04-10 2024-10-29 Quanterix Corporation Quantification of biomarkers present in physiological samples
EP3818081A4 (en) 2018-07-03 2022-06-22 University of Miami COMPOSITIONS AND METHODS FOR TREATING INFLAMMASOME-RELATED DISEASES OR DISORDERS
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN109406795A (zh) * 2018-11-20 2019-03-01 昆明医科大学 一种轻型脑外伤的血清分子诊断标记物及应用
CN113366318A (zh) * 2019-01-31 2021-09-07 日内瓦大学 创伤性脑损伤(tbi)的前瞻性标志物
WO2021071934A1 (en) * 2019-10-07 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Polymeric methylprednisolone conjugates and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545700A4 (en) * 2002-09-04 2006-09-27 Univ Washington METHOD FOR TREATING DAMAGE TO THE CENTRAL NERVOUS SYSTEM
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
CN101983337A (zh) * 2008-02-04 2011-03-02 班扬生物标记公司 用于诊断或治疗脑损伤的方法
AU2009271530B2 (en) * 2008-07-18 2016-01-07 Oxygen Biotherapeutics, Inc. Method of treating traumatic brain injury
US20120177632A1 (en) * 2011-01-10 2012-07-12 Shinohara Mari L Methods of optimizing disease treatment

Similar Documents

Publication Publication Date Title
JP2015508887A5 (enExample)
Green et al. Non-genetic and genetic risk factors for adult cerebral venous thrombosis
Aly et al. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome
Eijsvogel et al. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
JP2021505844A5 (enExample)
Wilking et al. Central nervous system manifestations in pediatric patients with influenza A H1N1 infection during the 2009 pandemic
JP6755240B2 (ja) 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法
CN106461645A (zh) 外伤性脑损伤和神经退行性生物标记物、方法和系统
JP6755241B2 (ja) 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法
JP2026016513A (ja) アルツハイマー病を判定するためのタンパク質マーカー
Tüzün et al. Enhanced complement consumption in neuromyelitis optica and Behcet's disease patients
KR20170062478A (ko) 우울증 치료약의 선택지를 예측하는 방법
WO2019117270A1 (ja) 頭頸部がんの検出を補助する方法
Amin et al. Identification of stage biomarkers for human African trypanosomiasis
CN110573174A (zh) 用于治疗脑损伤的方法和组合物
US10067142B2 (en) Method for diagnosing, treating, or preventing mood disorder
JP2018504909A5 (enExample)
Wei et al. The first human infection with severe fever with thrombocytopenia syndrome virus in Shaanxi Province, China
Cordeiro et al. Comparative proteomics of cerebrospinal fluid reveals a predictive model for differential diagnosis of pneumococcal, meningococcal, and enteroviral meningitis, and novel putative therapeutic targets
Barratt‐Due et al. Escalated complement activation during hospitalization is associated with higher risk of 60‐day mortality in SARS‐CoV‐2‐infected patients
Vittorakis et al. Circulating conventional and plasmacytoid dendritic cell subsets display distinct kinetics during in vivo repeated allergen skin challenges in atopic subjects
JP2017513021A5 (enExample)
EP3918336A1 (en) Prospective markers in traumatic brain injury (tbi)
JP2017521092A (ja) アルツハイマー病の診断検査及び治療／予防
ES2482866A1 (es) Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas